var data={"title":"Treatment protocols for hepatobiliary cancer","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment protocols for hepatobiliary cancer</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-hepatobiliary-cancer/contributors\" class=\"contributor contributor_credentials\">Tim Brenner, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-hepatobiliary-cancer/contributors\" class=\"contributor contributor_credentials\">Shrina Duggal, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-hepatobiliary-cancer/contributors\" class=\"contributor contributor_credentials\">Jim Natale, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-hepatobiliary-cancer/contributors\" class=\"contributor contributor_credentials\">Scott M Wirth, PharmD, BCOP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-hepatobiliary-cancer/contributors\" class=\"contributor contributor_credentials\">John W Mucenski, PharmD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-hepatobiliary-cancer/contributors\" class=\"contributor contributor_credentials\">Diane MF Savarese, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-hepatobiliary-cancer/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 28, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1090276\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with biliary cancer and hepatocellular cancer (HCC). <strong>This is</strong> <strong>not an exhaustive list</strong>; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with hepatobiliary cancer. Additional regimens may be added over time, particularly as treatment for hepatobiliary cancer evolves.</p><p>This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with hepatobiliary cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=systemic-therapy-for-advanced-cholangiocarcinoma\" class=\"medical medical_review\">&quot;Systemic therapy for advanced cholangiocarcinoma&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=treatment-of-advanced-unresectable-gallbladder-cancer\" class=\"medical medical_review\">&quot;Treatment of advanced, unresectable gallbladder cancer&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=ampullary-carcinoma-treatment-and-prognosis\" class=\"medical medical_review\">&quot;Ampullary carcinoma: Treatment and prognosis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=systemic-treatment-for-advanced-hepatocellular-carcinoma\" class=\"medical medical_review\">&quot;Systemic treatment for advanced hepatocellular carcinoma&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=adjuvant-treatment-for-localized-resected-gallbladder-cancer\" class=\"medical medical_review\">&quot;Adjuvant treatment for localized, resected gallbladder cancer&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=treatment-of-localized-cholangiocarcinoma-adjuvant-and-neoadjuvant-therapy-and-prognosis\" class=\"medical medical_review\">&quot;Treatment of localized cholangiocarcinoma: Adjuvant and neoadjuvant therapy and prognosis&quot;</a>.)</p><p/><p>These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</p><p class=\"headingAnchor\" id=\"H1090199\"><span class=\"h1\">REGIMENS</span></p><p class=\"headingAnchor\" id=\"H607000108\"><span class=\"h2\">Biliary or hepatocellular cancer (HCC)</span></p><p class=\"headingAnchor\" id=\"H934552054\"><span class=\"h3\">Short-term infusional fluorouracil plus leucovorin for advanced gastrointestinal cancer (modified de Gramont schedule)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F65525\" class=\"graphic graphic_table graphicRef65525 \">table 1</a>) </p><p class=\"headingAnchor\" id=\"H273751465\"><span class=\"h3\">Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F50132\" class=\"graphic graphic_table graphicRef50132 \">table 2</a>)</p><p class=\"headingAnchor\" id=\"H607000131\"><span class=\"h3\">Capecitabine and oxaliplatin for locally advanced or metastatic HCC or biliary cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F89431\" class=\"graphic graphic_table graphicRef89431 \">table 3</a>)</p><p class=\"headingAnchor\" id=\"H607000161\"><span class=\"h2\">Bilary tract cancer</span></p><p class=\"headingAnchor\" id=\"H934552083\"><span class=\"h3\">Single agent gemcitabine for adjuvant treatment of biliary tract cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F81436\" class=\"graphic graphic_table graphicRef81436 \">table 4</a>) </p><p class=\"headingAnchor\" id=\"H3458436164\"><span class=\"h3\">Gemcitabine and capecitabine (GEMCAP) followed by concurrent capecitabine and radiotherapy for adjuvant therapy of biliary tract cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F107377\" class=\"graphic graphic_table graphicRef107377 \">table 5</a>) </p><p class=\"headingAnchor\" id=\"H1090566\"><span class=\"h3\">Single agent gemcitabine for metastatic biliary tract cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F60330\" class=\"graphic graphic_table graphicRef60330 \">table 6</a>)</p><p class=\"headingAnchor\" id=\"H607000198\"><span class=\"h3\">Gemcitabine and cisplatin for locally advanced or metastatic biliary tract cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F89633\" class=\"graphic graphic_table graphicRef89633 \">table 7</a>)</p><p class=\"headingAnchor\" id=\"H607000264\"><span class=\"h3\">Gemcitabine and oxaliplatin (GEMOX) for locally advanced or metastatic biliary tract cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F90451\" class=\"graphic graphic_table graphicRef90451 \">table 8</a>)</p><p class=\"headingAnchor\" id=\"H4250970826\"><span class=\"h3\">Modified gemcitabine and oxaliplatin (GEMOX) for advanced gallbladder cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F111904\" class=\"graphic graphic_table graphicRef111904 \">table 9</a>)</p><p class=\"headingAnchor\" id=\"H490689721\"><span class=\"h3\">Gemcitabine and capecitabine (GEMCAP) for advanced biliary tract cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F103038\" class=\"graphic graphic_table graphicRef103038 \">table 10</a>)</p><p class=\"headingAnchor\" id=\"H1046579022\"><span class=\"h3\">FOLFIRI (fluorouracil plus leucovorin and irinotecan) plus bevacizumab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F64505\" class=\"graphic graphic_table graphicRef64505 \">table 11</a>)</p><p class=\"headingAnchor\" id=\"H607000227\"><span class=\"h2\">Hepatocellular cancer (HCC)</span></p><p class=\"headingAnchor\" id=\"H279079332\"><span class=\"h3\">Gemcitabine and pegylated liposomal doxorubicin for advanced HCC</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F89985\" class=\"graphic graphic_table graphicRef89985 \">table 12</a>)</p><p class=\"headingAnchor\" id=\"H27454953\"><span class=\"h3\">Gemcitabine and oxaliplatin (GEMOX) for advanced HCC</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F89385\" class=\"graphic graphic_table graphicRef89385 \">table 13</a>)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 85683 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H1090276\" id=\"outline-link-H1090276\">INTRODUCTION</a></li><li><a href=\"#H1090199\" id=\"outline-link-H1090199\">REGIMENS</a><ul><li><a href=\"#H607000108\" id=\"outline-link-H607000108\">Biliary or hepatocellular cancer (HCC)</a><ul><li><a href=\"#H934552054\" id=\"outline-link-H934552054\">- Short-term infusional fluorouracil plus leucovorin for advanced gastrointestinal cancer (modified de Gramont schedule)</a></li><li><a href=\"#H273751465\" id=\"outline-link-H273751465\">- Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)</a></li><li><a href=\"#H607000131\" id=\"outline-link-H607000131\">- Capecitabine and oxaliplatin for locally advanced or metastatic HCC or biliary cancer</a></li></ul></li><li><a href=\"#H607000161\" id=\"outline-link-H607000161\">Bilary tract cancer</a><ul><li><a href=\"#H934552083\" id=\"outline-link-H934552083\">- Single agent gemcitabine for adjuvant treatment of biliary tract cancer</a></li><li><a href=\"#H3458436164\" id=\"outline-link-H3458436164\">- Gemcitabine and capecitabine (GEMCAP) followed by concurrent capecitabine and radiotherapy for adjuvant therapy of biliary tract cancer</a></li><li><a href=\"#H1090566\" id=\"outline-link-H1090566\">- Single agent gemcitabine for metastatic biliary tract cancer</a></li><li><a href=\"#H607000198\" id=\"outline-link-H607000198\">- Gemcitabine and cisplatin for locally advanced or metastatic biliary tract cancer</a></li><li><a href=\"#H607000264\" id=\"outline-link-H607000264\">- Gemcitabine and oxaliplatin (GEMOX) for locally advanced or metastatic biliary tract cancer</a></li><li><a href=\"#H4250970826\" id=\"outline-link-H4250970826\">- Modified gemcitabine and oxaliplatin (GEMOX) for advanced gallbladder cancer</a></li><li><a href=\"#H490689721\" id=\"outline-link-H490689721\">- Gemcitabine and capecitabine (GEMCAP) for advanced biliary tract cancer</a></li><li><a href=\"#H1046579022\" id=\"outline-link-H1046579022\">- FOLFIRI (fluorouracil plus leucovorin and irinotecan) plus bevacizumab</a></li></ul></li><li><a href=\"#H607000227\" id=\"outline-link-H607000227\">Hepatocellular cancer (HCC)</a><ul><li><a href=\"#H279079332\" id=\"outline-link-H279079332\">- Gemcitabine and pegylated liposomal doxorubicin for advanced HCC</a></li><li><a href=\"#H27454953\" id=\"outline-link-H27454953\">- Gemcitabine and oxaliplatin (GEMOX) for advanced HCC</a></li></ul></li></ul></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/85683|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/65525\" class=\"graphic graphic_table\">- Modified de Gramont schedule for gastrointestinal cancer</a></li><li><a href=\"image.htm?imageKey=ONC/50132\" class=\"graphic graphic_table\">- Modified FOLFOX6</a></li><li><a href=\"image.htm?imageKey=ONC/89431\" class=\"graphic graphic_table\">- CAPOX hepatobiliary</a></li><li><a href=\"image.htm?imageKey=ONC/81436\" class=\"graphic graphic_table\">- Gemcitabine for nonmetastatic pancreatic and biliary cancer</a></li><li><a href=\"image.htm?imageKey=ONC/107377\" class=\"graphic graphic_table\">- Adjuvant GemCap with chemoradiotherapy EHCC or GCBA</a></li><li><a href=\"image.htm?imageKey=ONC/60330\" class=\"graphic graphic_table\">- Gemcitabine for metastatic pancreatic and biliary tract cancer</a></li><li><a href=\"image.htm?imageKey=ONC/89633\" class=\"graphic graphic_table\">- GemCis biliary tract</a></li><li><a href=\"image.htm?imageKey=ONC/90451\" class=\"graphic graphic_table\">- GEMOX biliary</a></li><li><a href=\"image.htm?imageKey=ONC/111904\" class=\"graphic graphic_table\">- Modified GEMOX for advanced gallbladder cancer</a></li><li><a href=\"image.htm?imageKey=ONC/103038\" class=\"graphic graphic_table\">- GemCap for advanced pancreatobiliary cancer</a></li><li><a href=\"image.htm?imageKey=ONC/64505\" class=\"graphic graphic_table\">- FOLFIRI plus bevacizumab</a></li><li><a href=\"image.htm?imageKey=ONC/89985\" class=\"graphic graphic_table\">- Gemcitabine plus PLD for HCC</a></li><li><a href=\"image.htm?imageKey=ONC/89385\" class=\"graphic graphic_table\">- GEMOX hepatic</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adjuvant-treatment-for-localized-resected-gallbladder-cancer\" class=\"medical medical_review\">Adjuvant treatment for localized, resected gallbladder cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ampullary-carcinoma-treatment-and-prognosis\" class=\"medical medical_review\">Ampullary carcinoma: Treatment and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-therapy-for-advanced-cholangiocarcinoma\" class=\"medical medical_review\">Systemic therapy for advanced cholangiocarcinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-treatment-for-advanced-hepatocellular-carcinoma\" class=\"medical medical_review\">Systemic treatment for advanced hepatocellular carcinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-advanced-unresectable-gallbladder-cancer\" class=\"medical medical_review\">Treatment of advanced, unresectable gallbladder cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-localized-cholangiocarcinoma-adjuvant-and-neoadjuvant-therapy-and-prognosis\" class=\"medical medical_review\">Treatment of localized cholangiocarcinoma: Adjuvant and neoadjuvant therapy and prognosis</a></li></ul></div></div>","javascript":null}